Comparison · NCT02743364-sae
Arm I (Simvastatin) vs Arm II (Placebo): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm I (Simvastatin) vs Arm II (Placebo): serious adverse events. Trial comparisons, record NCT02743364-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02743364-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.833 | 0.436 | 0.97 | wilson | |
| Risk in group 2 | 0.5 | 0.0945 | 0.905 | wilson | |
| Risk difference, group 1 minus group 2 | 0.333 | -0.234 | 0.761 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.67 | 0.398 | 6.97 | log | |
| Odds ratio, group 1 over group 2 | 5 | 0.15 | 167 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Arm I (Simvastatin) than on Arm II (Placebo) | 3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm I (Simvastatin) | Patients receive simvastatin PO QD for 6 months.~Laboratory Biomarker Analysis: Correlative studies~Quality-of-Life Assessment: Ancillary studies~Questionnaire Administration: Ancillary studies~Simvastatin: Given PO | 5 | 6 | EG000 |
| Group 2 | Arm II (Placebo) | Patients receive placebo PO QD for 6 months.~Laboratory Biomarker Analysis: Correlative studies~Placebo Administration: Given PO~Quality-of-Life Assessment: Ancillary studies~Questionnaire Administration: Ancillary studies | 1 | 2 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- AEs collected from the time informed consent was signed and baseline procedures were completed through 90 days post-intervention. In total AEs collected for a period of 9 months.
Source ClinicalTrials.gov
Trial
- Title
- Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis
- NCT number
- NCT02743364
- Phases
- PHASE2
- Conditions
- Acute Pancreatitis
- Interventions
- Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Simvastatin
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2022-01-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02743364?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02743364-sae